Novartis update: delpacibart etedesiran misses Phase III goal in HARBOR
Novartis provided an update on its delpacibart etedesiran Phase III HARBOR study in myotonic dystrophy type 1 (DM1), saying the neuromuscular drug candidate missed its late-stage trial goal.
(05:00 GMT) Novartis provided an update on delpacibart etedesiran, or del-desiran, from the Phase III HARBOR study in myotonic dystrophy type 1 (DM1). (05:20 GMT) Novartis said the neuromuscular drug candidate missed its goal in the late-stage trial.